Press Releases

A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.

Researchers have developed a new generation of microscopic particles for molecular imaging, constituting one of the first promising nanoparticle platforms that may be readily adapted for tumor targeting and treatment in the clinic.

Memorial Sloan Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene.

New findings from a Decision Analysis for the US Preventative Services Task Force (USPSTF) suggest that routine colorectal cancer screenings can be stopped in patients over the age of 75.

Memorial Sloan Kettering Cancer Center and Summit Medical Group together announce a new collaborative relationship for the care of people with cancer.

American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan Kettering Cancer Center.

New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments.

The recent marketing of "at home" genomic tests for disease risk may be premature, according to Dr. Kenneth Offit, MD, MPH, Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center (MSKCC).